![]() |
Converting Energy to Medical ProgressOak Ridge National Laboratory, TennesseeIn 1946, BER originated in Oak Ridge when the research site made a vast selection of radionuclides available for nuclear medicine research. The laboratory also formed a network of universities to study the clinical potential of radiotracers. Today, scientists here continue to study the future potential of new radiopharmaceuticals. This group has developed a variety of radiopharmaceuticals for both diagnostic and therapeutic applications. One example is a generator to produce rhenium-188, a therapeutic radionuclide used to provide economical cancer treatment in developing countries. Another potential use of rhenium-188 is to prolong the beneficial effects of balloon angioplasty, a procedure that opens up narrowed arteries of the heart in patients with coronary artery disease. Patients often need repeated angioplasties because the coronary arteries gradually become reclogged.
Using a fatty acid as the carrier molecule, Oak Ridge scientists have also developed a radiopharmaceutical (iodine-123 BMIPP) that shows how much heart muscle remains alive after a heart attack. These scans help doctors decide whether those portions of the heart muscle can recover after bypass surgery or angioplasty. |
|
Table of Contents * About BER * Many Patients * How Does It Work? * BER Medical * Future Healthcare * BNL * LBNL * ORNL * Sloan-Kettering * UCLA * Washington Univ. * Univ. of Michigan * 50-Years * Credits Published April 2001 |
Return to the MSD Research Home Page
Disclaimers
Tuesday, October 23, 2007
Webmaster